Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely.
https://www.pharmalive.com/wp-content/uploads/2023/02/ReutersPfizerCOVIDvax2-6-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-02-06 06:20:432023-02-06 10:08:07Drug companies face COVID cliff in 2023 as sales set to plummet
